Tinneke Delvaeye1,2,3, Maarten A J De Smet3, Stijn Verwaerde3, Elke Decrock3, Aleksandra Czekaj1,2, Roosmarijn E Vandenbroucke1,2, Kelly Lemeire1,2, Amanda Gonçalves1,2,4, Wim Declercq1,2, Peter Vandenabeele5,6,7, Dmitri V Krysko8, Luc Leybaert9. 1. VIB Center for Inflammation Research, Ghent, Belgium. 2. Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium. 3. Department of Basic and Applied Medical Sciences, Ghent University, Ghent, Belgium. 4. VIB BioImaging Core, Ghent, Belgium. 5. VIB Center for Inflammation Research, Ghent, Belgium. peter.vandenabeele@irc.vib-ugent.be. 6. Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium. peter.vandenabeele@irc.vib-ugent.be. 7. Methusalem Program, Ghent University, Ghent, Belgium. peter.vandenabeele@irc.vib-ugent.be. 8. Department of Human Structure and Repair, Ghent University, Ghent, Belgium. dmitri.krysko@ugent.be. 9. Department of Basic and Applied Medical Sciences, Ghent University, Ghent, Belgium. luc.leybaert@ugent.be.
Abstract
Upon intravenous injection of tumour necrosis factor (TNF) in mice, a systemic inflammatory response syndrome (SIRS) is initiated, characterized by an acute cytokine storm and induction of vascular hyperpermeability. Connexin43 hemichannels have been implicated in various pathological conditions, e.g. ischemia and inflammation, and can lead to detrimental cellular outcomes. Here, we explored whether targeting connexin43 hemichannels could alleviate TNF-induced endothelial barrier dysfunction and lethality in SIRS. Therefore, we verified whether administration of connexin43-targeting-peptides affected survival, body temperature and vascular permeability in vivo. In vitro, TNF-effects on connexin43 hemichannel function were investigated by single-channel studies and Ca2+-imaging. Blocking connexin43 hemichannels with TAT-Gap19 protected mice against TNF-induced mortality, hypothermia and vascular leakage, while enhancing connexin43 hemichannel function with TAT-CT9 provoked opposite sensitizing effects. In vitro patch-clamp studies revealed that TNF acutely activated connexin43 hemichannel opening in endothelial cells, which was promoted by CT9, and inhibited by Gap19 and intracellular Ca2+-buffering. In vivo experiments aimed at buffering intracellular Ca2+, and pharmacologically targeting Ca2+/calmodulin-dependent protein kinase-II, a known modulator of endothelial barrier integrity, demonstrated their involvement in permeability alterations. Our results demonstrate significant benefits of inhibiting connexin43 hemichannels to counteract TNF-induced SIRS-associated vascular permeability and lethality.
Upon intravenous injection of tumour necrosis factor (TNF) in mice, a systemic inflammatory response syndrome (SIRS) is initiated, characterized by an acute cytokine storm and induction of vascular hyperpermeability. Connexin43 hemichannels have been implicated in various pathological conditions, e.g. ischemia and inflammation, and can lead to detrimental cellular outcomes. Here, we explored whether targeting connexin43 hemichannels could alleviate TNF-induced endothelial barrier dysfunction and lethality in SIRS. Therefore, we verified whether administration of connexin43-targeting-peptides affected survival, body temperature and vascular permeability in vivo. In vitro, TNF-effects on connexin43 hemichannel function were investigated by single-channel studies and Ca2+-imaging. Blocking connexin43 hemichannels with TAT-Gap19 protected mice against TNF-induced mortality, hypothermia and vascular leakage, while enhancing connexin43 hemichannel function with TAT-CT9 provoked opposite sensitizing effects. In vitro patch-clamp studies revealed that TNF acutely activated connexin43 hemichannel opening in endothelial cells, which was promoted by CT9, and inhibited by Gap19 and intracellular Ca2+-buffering. In vivo experiments aimed at buffering intracellular Ca2+, and pharmacologically targeting Ca2+/calmodulin-dependent protein kinase-II, a known modulator of endothelial barrier integrity, demonstrated their involvement in permeability alterations. Our results demonstrate significant benefits of inhibiting connexin43 hemichannels to counteract TNF-induced SIRS-associated vascular permeability and lethality.
During TNF-induced SIRS, an exaggerated production and secretion of pro-inflammatory cytokines (e.g. interleukin 6 (IL-6), IL-1) and chemokines (CXCL-1) into the circulation results in the activation and increased permeability of the endothelium[1-4]. Endothelial cells (ECs) are connected by different junctional proteins that mediate vascular barrier function and intercellular communication[5]. The reorganization of tight and adherens junctions has been frequently linked to microvascular dysfunction and hyperpermeability, often induced by TNF and other inflammatory mediators[6-8]. However, little is known on the role of connexins (Cxs) and their channels, i.e. gap junction channels (GJCs) and hemichannels, in the pathogenesis of SIRS. GJCs consist of two hemichannels, each containing 6 Cx proteins. The latter are composed of four transmembrane regions, two extracellular loops, a cytoplasmic loop and cytosolic N- and C-terminal tails. Hemichannels provide a passageway between the intra- and extracellular environment, while GJCs connect the cytoplasm of two neighbouring cells, providing a route for direct cell-cell communication. Both hemichannels and GJCs allow the passage of ions and small molecules (≤1.5 kDa) such as adenosine trisphosphate (ATP) and inositol trisphosphate (IP3)[9,10]. Cx43 is the most abundant and widespread Cx in mammals, including in vascular ECs[11,12]. Cx43 hemichannels are primarily closed under physiological conditions[13,14]; however, they are reported to open upon various, mostly pathological stimuli such as ischemic or inflammatory conditions[15,16]. Given the large conductance of Cx43 hemichannels, excessive opening of these channels is expected to have deleterious consequences for the integrity of the cell due to dissipative electrical current flow, disturbed cellular ion homeostasis, Ca2+-entry and loss of crucial metabolites such as e.g. ATP or glutamate[17,18].Our aim was to investigate whether selectively targeting Cx43 hemichannels could rescue animals from TNF-induced SIRS, particularly from vascular leakage. We targeted Cx43 hemichannels in vivo by making use of TAT-Gap19[19] and TAT-CT9[20-22], respectively known to block or promote Cx43 hemichannel opening (for a review, see[11,23]). Gap19 and CT9 both have their targets inside the cell, at the C-terminal tail and cytoplasmic loop of Cx43, respectively, and are therefore fused to a translocation sequence (TAT) to improve their membrane permeation in vivo. Combined, our in vivo and in vitro approaches demonstrate that Cx43 hemichannels, through TNF-induced Ca2+-increases, lead to renal vascular permeability and animal mortality in SIRS.
Results
Blocking Cx43 hemichannels protects mice against TNF-induced mortality, hypothermia and vascular permeability alterations
The TNF-induced SIRS model was used to induce acute systemic inflammation, hypothermia and eventually death[1,4,24,25]. To address the role of Cx43 hemichannel opening, we injected TNF intravenously (i.v.) in C57BL/6J mice in the absence or presence of peptides modulating Cx43 hemichannel function. Prophylactic administration of Gap27 (25 mg/kg i.v.), a peptide mimicking a conserved domain on the second extracellular loop of various Cxs and known to first block hemichannels followed by delayed GJC block[26], significantly protected 50% of the mice against TNF-induced hypothermia and mortality (Fig. 1a). To more specifically target Cx43 hemichannels, we prophylactically administered TAT-Gap19[19] (5 mg/kg i.v.) and obtained significant protection against hypothermia and mortality (Fig. 1b). Injecting TAT-Gap19 30 min after TNF also significantly protected mice against hypothermia, and led to a smaller but significant reduction in micemortality (17% vs 50% when administered prophylactically) (Supplemental Fig. 1a,b). Since vascular hyperpermeability is a major pathophysiological feature of SIRS[3,27], we assessed the integrity of the endothelial barrier. For this, FITC-dextran was administered i.v. 5 hr post-TNF, and was removed from the blood vessels via transcardial perfusion, after which different organs were isolated to assess overall FITC-dextran leakage (Supplemental Fig. 2a). A significant increase in vascular permeability in colon, ileum, lungs and kidneys was detected 6 hr post-TNF injection (Supplemental Fig. 2b). Interestingly, blocking Cx43 hemichannels by TAT-Gap19 (5 mg/kg) impeded the TNF-induced increase in vascular permeability in the kidney (Fig. 1c), suggesting that Cx43 hemichannels open upon TNF injection, and thus contribute to vascular leakage during SIRS.
Figure 1
(a) Blocking Cx channels by Gap27 protects mice against TNF-induced mortality and hypothermia. Cumulative survival rates and body temperatures as a function of time. Male C57BL/6J mice were injected i.v. with Gap27 (25 mg/kg) or vehicle (DPBS) 15 min prior to i.v. injection of TNF (LD100). Pool of 2 independent experiments. The one-star differences in the left and right panel have p-values of 0.0212 and 0.0338, respectively; **p = 0.0043, ****p < 0.0001. (b,c) Blocking Cx43 hemichannels protects mice against TNF-induced mortality, hypothermia and renal vascular permeability alterations. Male C57BL/6J mice were pre-injected i.v. with the indicated peptides 15 min prior to i.v. injection of TNF (LD70); n = total number of mice per group. (b) Cumulative survival rates and body temperatures presented as a function of time. Pool of 4 independent experiments. A significant protection is observed upon selective Cx43 hemichannel blockade by TAT-Gap19, when compared to pre-treatment with vehicle (**p = 0.0022) or TAT (**p = 0.0067). The two-star difference (right panel) equals a p-value of 0.0019; ****p < 0.0001. LD70 = lethal dose for 70% of mice in control group (Vehicle + TNF). (c) Vascular permeability shown as relative light units (RLU) of FITC-dextran in colon, ileum, lungs and kidneys 6 hr after injection of vehicle or TNF. Pool of 2 independent experiments. The two-star difference corresponds to a p-value of 0.0073; ****p < 0.0001. (d,e) Stimulating Cx43 hemichannel opening accelerates TNF-induced mortality, hypothermia and vascular permeability increase. Male C57BL/6J mice were pre-injected i.v. with the indicated peptides 15 min prior to i.v. injection of a sub-lethal dose of TNF (LD0); n = total number of mice per group. (d) Survival and body temperature presented as a function of time. Mice receiving TAT-CT9 are sensitized towards TNF-induced lethality, when compared to mice pre-treated with TAT-Gap19 (**p = 0.0074), TAT (**p = 0.0034) and 10 mg/kg TAT-Gap19 + TAT-CT9 (**p = 0.0034) (d; left panel). The two-star difference in (d; right panel) corresponds to a p-value of 0.0078; ****p < 0.0001. LD0 = non-lethal dose for mice in control group (TAT + TNF). (e) Vascular permeability shown as RLU of FITC-dextran in colon, ileum, lungs and kidneys 6 hr after injection of vehicle or TNF. The one-star difference corresponds to a p-value of 0.0256, the two-star difference has a p-value of 0.0077. Data are presented as mean ± SEM. Statistical tests used: (a (left), b (left), d (left)): Mantel-Cox test; a (right): 2-Way ANOVA with post-hoc Sidak's test; (b (right), c,d (right), e): 2-Way ANOVA with post-hoc Tukey’s test.
(a) Blocking Cx channels by Gap27 protects mice against TNF-induced mortality and hypothermia. Cumulative survival rates and body temperatures as a function of time. Male C57BL/6J mice were injected i.v. with Gap27 (25 mg/kg) or vehicle (DPBS) 15 min prior to i.v. injection of TNF (LD100). Pool of 2 independent experiments. The one-star differences in the left and right panel have p-values of 0.0212 and 0.0338, respectively; **p = 0.0043, ****p < 0.0001. (b,c) Blocking Cx43 hemichannels protects mice against TNF-induced mortality, hypothermia and renal vascular permeability alterations. Male C57BL/6J mice were pre-injected i.v. with the indicated peptides 15 min prior to i.v. injection of TNF (LD70); n = total number of mice per group. (b) Cumulative survival rates and body temperatures presented as a function of time. Pool of 4 independent experiments. A significant protection is observed upon selective Cx43 hemichannel blockade by TAT-Gap19, when compared to pre-treatment with vehicle (**p = 0.0022) or TAT (**p = 0.0067). The two-star difference (right panel) equals a p-value of 0.0019; ****p < 0.0001. LD70 = lethal dose for 70% of mice in control group (Vehicle + TNF). (c) Vascular permeability shown as relative light units (RLU) of FITC-dextran in colon, ileum, lungs and kidneys 6 hr after injection of vehicle or TNF. Pool of 2 independent experiments. The two-star difference corresponds to a p-value of 0.0073; ****p < 0.0001. (d,e) Stimulating Cx43 hemichannel opening accelerates TNF-induced mortality, hypothermia and vascular permeability increase. Male C57BL/6J mice were pre-injected i.v. with the indicated peptides 15 min prior to i.v. injection of a sub-lethal dose of TNF (LD0); n = total number of mice per group. (d) Survival and body temperature presented as a function of time. Mice receiving TAT-CT9 are sensitized towards TNF-induced lethality, when compared to mice pre-treated with TAT-Gap19 (**p = 0.0074), TAT (**p = 0.0034) and 10 mg/kg TAT-Gap19 + TAT-CT9 (**p = 0.0034) (d; left panel). The two-star difference in (d; right panel) corresponds to a p-value of 0.0078; ****p < 0.0001. LD0 = non-lethal dose for mice in control group (TAT + TNF). (e) Vascular permeability shown as RLU of FITC-dextran in colon, ileum, lungs and kidneys 6 hr after injection of vehicle or TNF. The one-star difference corresponds to a p-value of 0.0256, the two-star difference has a p-value of 0.0077. Data are presented as mean ± SEM. Statistical tests used: (a (left), b (left), d (left)): Mantel-Cox test; a (right): 2-Way ANOVA with post-hoc Sidak's test; (b (right), c,d (right), e): 2-Way ANOVA with post-hoc Tukey’s test.
To assess whether increased hemichannel opening would worsen lethality and vascular permeability, TAT-CT9 peptide that mimics part of the C-terminal tail of Cx43 and promotes Cx43 hemichannel opening, was used[20,22]. When mice were challenged with sub-lethal doses of TNF, TAT-CT9 (10 mg/kg i.v.) sensitized mice to TNF, leading to 100% mortality and stronger hypothermia (Fig. 1d) and furthermore significantly increased vascular permeability in the kidney, when compared to vehicle-treated mice (Fig. 1e). Interestingly, when both TAT-Gap19 and TAT-CT9 were combined at equimolar concentrations (10 mg/kg), TAT-Gap19 counteracted the sensitization effect of TAT-CT9, while increasing the TAT-CT9 concentration to 15 mg/kg, combined with 10 mg/kg TAT-Gap19, again increased hypothermia and mortality (Fig. 1d).
TAT-Gap19 protection against renal vascular leakage is not accompanied by a reduction in cytokine and chemokine production, tissue damage, and release of cell death markers
Since excessive Cx43 hemichannel opening may disturb the transmembrane balance of various ions and molecules, we investigated whether open hemichannels may lead to cell death[28]. To examine this end-point and the overall inflammatory state, the circulating levels of lactate dehydrogenase (LDH), reporting cell lysis, and pro-inflammatory cytokines and chemokines such as IL-6 and CXCL-1 were analysed 6 hr post-TNF. Increased levels of LDH, IL-6 and CXCL-1, as well as of P-selectin, marking EC activation, were observed (Fig. 2a–c). However, TAT-Gap19 (5 mg/kg) had no significant effect on these parameters (Fig. 2a–c). We further examined renal cell death by TUNEL assays, and surprisingly found no significant increase in TUNEL positivity following TNF compared to vehicle, suggesting TNF does not induce cell death in the kidneys 6 hr after TNF (Fig. 2d). Moreover, interfering with hemichannels by TAT-Gap19 or TAT-CT9 did not influence renal cell death levels after TNF (Fig. 2d). These data show that cell death is not the major cause for the increased renal vascular permeability, and that Cx43 hemichannels are not directly acting on the inflammatory and/or cell death cascades.
Figure 2
TAT-Gap19 protection against renal vascular leakage is not accompanied by a reduction in cytokine and chemokine production, tissue damage, and release of cell death markers. (a–c) Male C57BL/6J mice were pre-treated i.v. with vehicle (DPBS) or TAT-Gap19 (5 mg/kg) 15 minutes prior to TNF injection (10 µg, i.v.). n = total number of mice per group. (a) Levels of IL-6 and CXCL-1 in plasma of mice, 6 hr after TNF. (b) EC activation, displayed as plasma P-selectin levels 6 hr after TNF. (c) Tissue damage presented as levels of LDH in serum of mice, 6 hr after TNF. (d) Vehicle, TAT-Gap19 (10 mg/kg), TAT-CT9 (10 mg/kg) or TAT (10 mg/kg) were injected 15 min prior to TNF injection (10 µg, i.v.). Kidneys were isolated 6 hr after TNF. The data are represented as the ratio of TUNEL positive cells on all cells (Hoechst+) (in %). n = 5 mice per group; 1–3 sections per mouse; ***p < 0.0003, ****p < 0.0001. All data are presented as mean ± SEM. Statistical tests used: (a–d) 1-Way ANOVA with post-hoc Tukey’s test.
TAT-Gap19 protection against renal vascular leakage is not accompanied by a reduction in cytokine and chemokine production, tissue damage, and release of cell death markers. (a–c) Male C57BL/6J mice were pre-treated i.v. with vehicle (DPBS) or TAT-Gap19 (5 mg/kg) 15 minutes prior to TNF injection (10 µg, i.v.). n = total number of mice per group. (a) Levels of IL-6 and CXCL-1 in plasma of mice, 6 hr after TNF. (b) EC activation, displayed as plasma P-selectin levels 6 hr after TNF. (c) Tissue damage presented as levels of LDH in serum of mice, 6 hr after TNF. (d) Vehicle, TAT-Gap19 (10 mg/kg), TAT-CT9 (10 mg/kg) or TAT (10 mg/kg) were injected 15 min prior to TNF injection (10 µg, i.v.). Kidneys were isolated 6 hr after TNF. The data are represented as the ratio of TUNEL positive cells on all cells (Hoechst+) (in %). n = 5 mice per group; 1–3 sections per mouse; ***p < 0.0003, ****p < 0.0001. All data are presented as mean ± SEM. Statistical tests used: (a–d) 1-Way ANOVA with post-hoc Tukey’s test.
TNF activates and promotes Cx43 hemichannel opening in a Ca2+-dependent manner
As TAT-Gap19 and TAT-CT9 respectively led to protection and sensitisation against hypothermia, mortality and permeability in vivo, we further analysed the effect of TNF on Cx43 hemichannel function using whole-cell voltage clamp on HeLa cells stably overexpressing Cx43[14,19,29] and EA.hy926human ECs. In HeLa-Cx43 cells, voltage steps to +70 mV provoked unitary currents with a unitary conductance (γ0) of ~220 pS, consistent with the opening of Cx43 hemichannels (Fig. 3a).
Figure 3
TNF promotes opening of Cx43 hemichannels in a Ca2+-dependent manner. (a) Example traces and matching all-point histograms depicting typical Vm-induced (+70 mV, 30 s) Cx43 hemichannel unitary current activity recorded in solitary HeLa-Cx43 cells before, during and after application of human TNF (10 ng/ml) via a fast local perfusion system. Histograms illustrate conductance distributions centred around ~220 pS and multiples thereof. Dashed boxes right of the histograms correspond to boxed areas shown on the traces, demonstrating unitary channel closing events (conductance jumps of ~220 pS) in the tail currents following repolarization. (b) Qm summary data at baseline, during 0 ng/ml (black trace) or 10 ng/ml acute TNF (red trace) exposure and following washout (ncells = 10; 6 independent experiments). ‘#’ indicates significant difference in Qm during 0 and 10 ng/ml TNF. (c) Graph as shown in (b) but based on tail current unitary event counting as a measure channel activity (n and # as in b). (d) Representative current traces for different TNF concentrations. (e) Dose-response relationship for TNF stimulation of unitary current activity (ncells = 10 per concentration; 6 independent experiments). Different concentrations were compared to 0 ng/ml and fitted to a sigmoidal function. (f) Representative current traces illustrating the effect of Gap19, CT9 or BAPTA in baseline and in the presence of 100 ng/ml TNF (100 µM Gap19, 100 µM CT9 and 10 mM BAPTA intracellularly applied through the patch pipette). (g) Qm summary data of (f) (ncells = 15 per condition; 5 independent experiments). ‘#’ indicates significance as compared to baseline condition. ‘*’ indicates significance between conditions indicated by brackets. In (b,c,e,g), data are presented as mean ± SEM. Statistical tests used: (b,c) Repeated measures ANOVA with Dunnett’s post-hoc test; (e) 1-Way ANOVA and Bonferroni post-hoc test; (g) 2-tailed paired t-test or 1-Way ANOVA with Bonferroni post-hoc test, where applicable.
TNF promotes opening of Cx43 hemichannels in a Ca2+-dependent manner. (a) Example traces and matching all-point histograms depicting typical Vm-induced (+70 mV, 30 s) Cx43 hemichannel unitary current activity recorded in solitary HeLa-Cx43 cells before, during and after application of humanTNF (10 ng/ml) via a fast local perfusion system. Histograms illustrate conductance distributions centred around ~220 pS and multiples thereof. Dashed boxes right of the histograms correspond to boxed areas shown on the traces, demonstrating unitary channel closing events (conductance jumps of ~220 pS) in the tail currents following repolarization. (b) Qm summary data at baseline, during 0 ng/ml (black trace) or 10 ng/ml acute TNF (red trace) exposure and following washout (ncells = 10; 6 independent experiments). ‘#’ indicates significant difference in Qm during 0 and 10 ng/ml TNF. (c) Graph as shown in (b) but based on tail current unitary event counting as a measure channel activity (n and # as in b). (d) Representative current traces for different TNF concentrations. (e) Dose-response relationship for TNF stimulation of unitary current activity (ncells = 10 per concentration; 6 independent experiments). Different concentrations were compared to 0 ng/ml and fitted to a sigmoidal function. (f) Representative current traces illustrating the effect of Gap19, CT9 or BAPTA in baseline and in the presence of 100 ng/ml TNF (100 µM Gap19, 100 µM CT9 and 10 mM BAPTA intracellularly applied through the patch pipette). (g) Qm summary data of (f) (ncells = 15 per condition; 5 independent experiments). ‘#’ indicates significance as compared to baseline condition. ‘*’ indicates significance between conditions indicated by brackets. In (b,c,e,g), data are presented as mean ± SEM. Statistical tests used: (b,c) Repeated measures ANOVA with Dunnett’s post-hoc test; (e) 1-Way ANOVA and Bonferroni post-hoc test; (g) 2-tailed paired t-test or 1-Way ANOVA with Bonferroni post-hoc test, where applicable.Within 40 s after application of 10 ng/ml TNF, the unitary currents doubled in associated membrane charge transfer, Qm, and the number of hemichannel closing events in the tail currents (Fig. 3a–c). Upon TNF washout, unitary currents reverted to baseline within 40 s; control experiments without TNF or with TNF on HeLa-wildtype (WT) cells had no effect (Supplemental Fig. 3a,b). TNF dose-dependently increased unitary currents with a maximum (~4-fold increase) at 100 ng/ml TNF, and a half-maximal effect (EC50) at ~7.31 ng/ml TNF (Hill coefficient = 3) (Fig. 3d,e). Moreover, Gap19 and CT9 (100 µM) respectively blocked or enhanced TNF-potentiated Cx43 hemichannel activity (Fig. 3f,g). TNF is known to provoke changes of intracellular Ca2+ concentration ([Ca2+]i)[30,31], that may modulate Cx43 hemichannel opening[32]. Accordingly, Ca2+-imaging experiments on HeLa-Cx43 cells demonstrated Ca2+-oscillations in response to 100 ng/ml TNF (Supplemental Fig. 3c,d), and the TNF-induced increase in Qm was prevented by the intracellular application of the Ca2+-chelator BAPTA (10 mM) (p < 0.001) (Fig. 3f,g).We next tested in EA.hy926 ECs whether TNF could induce hemichannel opening by itself without electrical stimulation and whether [Ca2+]i played a role in activation. At normal resting 50 nM [Ca2+]i, unitary currents only appeared at +60 mV but at higher [Ca2+]i (250 or 500 nM), unitary currents additionally appeared at more physiological negative membrane potential (Fig. 4a). Upon increasing [Ca2+]i further to 1 µM, hemichannel activities again decreased to the level observed at 50 nM (Fig. 4a). A plot of unitary current amplitudes at 500 nM [Ca2+]i, as a function of voltage was characterized by a slope conductance of 222 ± 1 pS, supporting Cx43 hemichannel activity (Fig. 4b). Plotting Qm as a function of [Ca2+]i gave a bell-shaped relation with high hemichannel activity at 500 nM [Ca2+]i and low activity at 50 nM and 1 µM for both negative and positive voltages (Fig. 4d). Gap19 abolished hemichannel activity at 500 nM [Ca2+]i and CT9 enhanced low hemichannel activity at 1 µM [Ca2+]i (Fig. 4c,d). Histogram analysis of unitary currents demonstrated a single-channel conductance of ~220 pS for both control and CT9 (Fig. 4c). Collectively, these observations demonstrate [Ca2+]i-controlled Cx43 hemichannel opening[20,33]. Finally and most importantly, challenging EA.hy926 cells held at −50 mV resting potential with 100 ng/mL TNF triggered unitary currents with a ~220 pS unitary conductance, which were enhanced by CT9, and abolished by Gap19 and BAPTA[Ca2+]i-buffering, demonstrating Ca2+-dependent activation (Fig. 5a–c).
Figure 4
Vm- and [Ca2+]i-dependent activation of Cx43 hemichannels in EA.hy926 cells. (a) Example traces depicting unitary current activities during 30 s incremental Vm steps (−60 to +60 mv in 20 mV increments) for different (50, 250, 500 and 1000 nM) [Ca2+]i in solitary EA.hy926 cells. Increasing [Ca2+]i to 250 or 500 nM clearly activated unitary current activities at negative Vm and promoted unitary current activities at positive Vm; unitary currents disappear at 1 µM [Ca2+]i. (b) I-V plot of unitary current activities from experiments shown in a, demonstrating a slope conductance of 222 ± 1 pS (Nindependent experiments = 6; ncells = 21) characteristic for Cx43 hemichannels. (c) Respresentative current traces and corresponding all-point histograms at 500 or 1000 nM [Ca2+]i with, respectively, 100 µM Gap19 or CT9 (control traces see 500 nM [Ca2+]i panel a). (d) Qm summary data for incremental Vm step protocols as illustrated in a and c (Nindependent experiments = 6; ncells = 11–24 per condition), showing increased hemichannel activity with 250 and 500 nM [Ca2+]i and decreased activity at 1 µM. Gap19 (100 µM) blocked hemichannel activity at 500 nM [Ca2+]i and CT9 enhanced hemichannel activity at 1 µM [Ca2+]i. Data are expressed as mean ± SEM. Comparisons were performed using a one-way ANOVA with bonferroni post-hoc test (for [Ca2+]i dependency) or two-tailed unpaired t-test for Gap19 or CT9 versus 500 nM or 1µM [Ca2+]i. ‘*’ indicates significance of 500 nM [Ca2+]i vs 50 nM [Ca2+]i. ‘#” indicates significance of 1 µM [Ca2+]i vs 500 nM [Ca2+]i. ‘$’ indicates significance for Gap19 or CT9 versus respective control condition.
Figure 5
TNF rapidly activates Cx43 hemichannel opening in EA.hy926 cells via a Ca2+-dependent mechanism. (a) Consecutive current traces obtained at −50 mV (60 s) with and without 100 ng/mL TNF in solitary EA.hy926 cells. TNF induced periodic burst opening of ~220 pS unitary current activity, which was blocked by 100 µM Gap19 or 10 mM BAPTA, and enhanced by 100 µM CT9 (applied via the pipette solution). (b) Inset with corresponding all-point histogram demonstrating unitary activity characterized by a ~220 pS conductance. (c) Qm summary data of a (ncells = 8–13 per condition; 6 independent experiments). Data are expressed as mean ± SEM. ‘#’ indicates significance as compared to baseline condition, two-tailed paired student t test was used. ‘*’ indicates significance versus control TNF recording (2nd bar), one-way ANOVA with Dunnett’s multiple comparison test was used.
Vm- and [Ca2+]i-dependent activation of Cx43 hemichannels in EA.hy926 cells. (a) Example traces depicting unitary current activities during 30 s incremental Vm steps (−60 to +60 mv in 20 mV increments) for different (50, 250, 500 and 1000 nM) [Ca2+]i in solitary EA.hy926 cells. Increasing [Ca2+]i to 250 or 500 nM clearly activated unitary current activities at negative Vm and promoted unitary current activities at positive Vm; unitary currents disappear at 1 µM [Ca2+]i. (b) I-V plot of unitary current activities from experiments shown in a, demonstrating a slope conductance of 222 ± 1 pS (Nindependent experiments = 6; ncells = 21) characteristic for Cx43 hemichannels. (c) Respresentative current traces and corresponding all-point histograms at 500 or 1000 nM [Ca2+]i with, respectively, 100 µM Gap19 or CT9 (control traces see 500 nM [Ca2+]i panel a). (d) Qm summary data for incremental Vm step protocols as illustrated in a and c (Nindependent experiments = 6; ncells = 11–24 per condition), showing increased hemichannel activity with 250 and 500 nM [Ca2+]i and decreased activity at 1 µM. Gap19 (100 µM) blocked hemichannel activity at 500 nM [Ca2+]i and CT9 enhanced hemichannel activity at 1 µM [Ca2+]i. Data are expressed as mean ± SEM. Comparisons were performed using a one-way ANOVA with bonferroni post-hoc test (for [Ca2+]i dependency) or two-tailed unpaired t-test for Gap19 or CT9 versus 500 nM or 1µM [Ca2+]i. ‘*’ indicates significance of 500 nM [Ca2+]i vs 50 nM [Ca2+]i. ‘#” indicates significance of 1 µM [Ca2+]i vs 500 nM [Ca2+]i. ‘$’ indicates significance for Gap19 or CT9 versus respective control condition.TNF rapidly activates Cx43 hemichannel opening in EA.hy926 cells via a Ca2+-dependent mechanism. (a) Consecutive current traces obtained at −50 mV (60 s) with and without 100 ng/mL TNF in solitary EA.hy926 cells. TNF induced periodic burst opening of ~220 pS unitary current activity, which was blocked by 100 µM Gap19 or 10 mM BAPTA, and enhanced by 100 µM CT9 (applied via the pipette solution). (b) Inset with corresponding all-point histogram demonstrating unitary activity characterized by a ~220 pS conductance. (c) Qm summary data of a (ncells = 8–13 per condition; 6 independent experiments). Data are expressed as mean ± SEM. ‘#’ indicates significance as compared to baseline condition, two-tailed paired student t test was used. ‘*’ indicates significance versus control TNF recording (2nd bar), one-way ANOVA with Dunnett’s multiple comparison test was used.
Ca2+ and CaMKII are implicated in TNF-induced renal vascular permeability
Next, we investigated the role of intracellular Ca2+ in TNF-induced SIRS in vivo by [Ca2+]i chelation with ester-loaded BAPTA-AM (2 mM i.v.)[34], and found that it did not protect mice against mortality, but significantly ameliorated body temperatures (Fig. 6a,b), and protected against renal vascular leakage (Fig. 6c).
Figure 6
Ca2+ and CaMKII are implicated in TNF-induced renal vascular permeability. (a–c) Male C57BL/6J mice were pre-injected i.v. with vehicle (6% DMSO in DPBS) or BAPTA-AM (2 mM in DPBS) 30 min prior to i.v. injection of TNF (LD80); control condition is BAPTA-AM injected (i.v., 2 mM) without TNF; n = total number of mice per group. (a,b) Cumulative survival rates and body temperatures presented as a function of time. Pool of 3 independent experiments; *p = 0.0324. (c) Vascular permeability shown as RLU of FITC-dextran in colon, ileum, lungs and kidneys 6 hr after injection of control (BAPTA-AM) or TNF. Pool of 2 independent experiments. Colon: **p = 0.0086, ***p = 0.0003; Lungs: *p = 0.0469; Kidney: ****p < 0.0001, *p = 0.0108; **p = 0.0017. (d) Male C57BL/6J mice were injected i.v. with vehicle (6% DMSO in DPBS) or KN-93 (10 mg/kg) 60 min prior to i.v. injection of TNF. Mice pre-treated with KN-93 are slightly (p = 0.069) protected against renal vascular leakage. The two-star difference equals a p-value of 0.0034. In (b–d), data are presented as mean ± SEM. The statistical tests used: (a) Mantel-Cox test; (b,c) 2-Way ANOVA with post-hoc Tukey’s test; (d) 1-Way ANOVA with post-hoc Tukey’s test.
Ca2+ and CaMKII are implicated in TNF-induced renal vascular permeability. (a–c) Male C57BL/6J mice were pre-injected i.v. with vehicle (6% DMSO in DPBS) or BAPTA-AM (2 mM in DPBS) 30 min prior to i.v. injection of TNF (LD80); control condition is BAPTA-AM injected (i.v., 2 mM) without TNF; n = total number of mice per group. (a,b) Cumulative survival rates and body temperatures presented as a function of time. Pool of 3 independent experiments; *p = 0.0324. (c) Vascular permeability shown as RLU of FITC-dextran in colon, ileum, lungs and kidneys 6 hr after injection of control (BAPTA-AM) or TNF. Pool of 2 independent experiments. Colon: **p = 0.0086, ***p = 0.0003; Lungs: *p = 0.0469; Kidney: ****p < 0.0001, *p = 0.0108; **p = 0.0017. (d) Male C57BL/6J mice were injected i.v. with vehicle (6% DMSO in DPBS) or KN-93 (10 mg/kg) 60 min prior to i.v. injection of TNF. Mice pre-treated with KN-93 are slightly (p = 0.069) protected against renal vascular leakage. The two-star difference equals a p-value of 0.0034. In (b–d), data are presented as mean ± SEM. The statistical tests used: (a) Mantel-Cox test; (b,c) 2-Way ANOVA with post-hoc Tukey’s test; (d) 1-Way ANOVA with post-hoc Tukey’s test.Open Cx43 hemichannels form a release pathway for ATP[35], which may subsequently activate autocrine or paracrine signaling via purinergic P2X- and P2Y-receptors[36], thereby inducing Ca2+-increases in nearby cells that may provoke a propagation of hemichannel opening[37]. We thus tested whether P2X-/P2Y-receptor interference with PPADS, a broad-spectrum P2 receptor antagonist conferred protection against TNF-induced SIRS. PPADS (50 mg/kg i.p.) was found to significantly protect against hypothermia, visible after 6 hr and maintained until 24 hr, and against mortality (Supplemental Fig. 4). In a second instance, we assessed the role of CaMKII during TNF-induced SIRS as it is a known modulator of endothelial barrier integrity[38]. We found that the CaMKII inhibitor KN-93 (10 mg/kg i.v.) decreased TNF-induced renal vascular leakage, suggesting that CaMKII may be implicated in this process (Figs 6d and 7).
Figure 7
TNF-induced cytoplasmic changes in Ca2+ signaling with subsequent hemichannel opening contributes to vascular disruption. Schematic overview of TNF-induced Ca2+ changes, leading to hemichannel opening in ECs² and other cells, further promoting Ca2+-entry (orange). High intracellular Ca2+ concentrations (>500 nM) negatively regulate hemichannel opening, providing a negative feedback (orange) (reviewed in[23]). Hemichannel opening is also associated with ATP-release, which activates purinergic signaling through P2X-and P2Y-receptors, followed by the spreading of cytoplasmic Ca2+ alterations to neighboring cells. Intercellular movement of IP3 through GJCs may contribute to this spreading (reviewed in[38]). Ca2+ signaling is implicated in CaMKII-activation and auto-phosphorylation, and subsequent endothelial barrier integrity. Both Ca2+-buffering by BAPTA-AM, CaMKII inhibition by KN-93 and blocking of Cx43 hemichannels by TAT-Gap19 (blue) protect cells against vascular leakage, while TAT-CT9 (dark red) promotes hemichannel opening and thus accelerates leakage.
TNF-induced cytoplasmic changes in Ca2+ signaling with subsequent hemichannel opening contributes to vascular disruption. Schematic overview of TNF-induced Ca2+ changes, leading to hemichannel opening in ECs² and other cells, further promoting Ca2+-entry (orange). High intracellular Ca2+ concentrations (>500 nM) negatively regulate hemichannel opening, providing a negative feedback (orange) (reviewed in[23]). Hemichannel opening is also associated with ATP-release, which activates purinergic signaling through P2X-and P2Y-receptors, followed by the spreading of cytoplasmic Ca2+ alterations to neighboring cells. Intercellular movement of IP3 through GJCs may contribute to this spreading (reviewed in[38]). Ca2+ signaling is implicated in CaMKII-activation and auto-phosphorylation, and subsequent endothelial barrier integrity. Both Ca2+-buffering by BAPTA-AM, CaMKII inhibition by KN-93 and blocking of Cx43 hemichannels by TAT-Gap19 (blue) protect cells against vascular leakage, while TAT-CT9 (dark red) promotes hemichannel opening and thus accelerates leakage.
Discussion
Our results indicate involvement of Cx43 hemichannels in TNF-induced SIRS pathology. First, TAT-Gap19 significantly protected mice against mortality, hypothermia and renal vascular permeability, while stimulating hemichannel opening with TAT-CT9 exhibited opposite effects and sensitized mice to TNF. Electrophysiological evidence demonstrated a fast stimulatory effect of TNF on Cx43 hemichannel opening, which was linked to [Ca2+]i-dynamics. In vivo, [Ca2+]i-buffering with BAPTA-AM also protected against renal vascular leakage and hypothermia, and we identified ATP and CaMKII as possible intermediate actors in triggering renal vascular leakage. Collectively, these data assign a new role to Cx43 hemichannels in accelerating renal vascular permeability and mortality during TNF-induced SIRS.Cx43 channels have previously been implicated in vascular permeability alterations based on in vivo observations under inflammatory or ischemic conditions[39-41] based on work with extracellular loop mimetic peptides, such as Peptide-5, Gap26 or Gap27[11]. However, these peptides may affect various Cx isotypes distinct from Cx43 which is a prototypic Cx involved in inflammation. Similarly, Zhang et al. reported a relationship between Cx43 and renal permeability in response to cecal-ligation and puncture (CLP), making use of carbenoxolone[39], which inhibits both GJCs and hemichannels, but also affects many other targets[42,43]. Here, we demonstrated a significant impact of selective Cx43 hemichannel blockade via TAT-Gap19 on renal vascular permeability. Other studies linked an increased ex vivo Cx43 expression in rat kidneys upon lipopolysaccharide treatment to a pro-inflammatory effect[44], and showed an upregulation of Cx43 in chronic kidney disease, which was associated with increased pro-inflammatory signalling[45]. However, in these studies, Cx43 hemichannel functionality was not addressed.Circulating peptides are rapidly cleared from the blood suggesting that the protective effect of TAT-Gap19 on mortality occurring over a time span of several days involves an early and crucial event. Of interest, in a model of mild CLP in Balb/c mice, Gap26 and TAT-Gap19 exhibited opposite effects, with Gap26 being protective and TAT-Gap19 worsening mortality[46]. However, the TAT-Gap19 doses used were very high (up to 120 mg/kg compared to 5 mg/kg in this study).TAT-CT9, which enhances hemichannel opening[20,21], was used to contrast the TAT-Gap19 effects, and was shown to sensitize the TNF-induced phenotype in vivo. To understand the opposite effects of TAT-Gap19 and TAT-CT9, we investigated the modulating effect of TNF on hemichannel activity through electrophysiological recording and found that TNF rapidly and dose-dependently stimulated Cx43 hemichannel opening, via [Ca2+]i-elevation. These findings demonstrate that Cx43 hemichannel opening is an early event that may crucially affect the outcome, as exemplified by the strong protective effect of a single injection of TAT-Gap19 on long lasting outcome measurements such as mortality.It is well known that Cx hemichannels are also involved as a pathway for ATP-release[35,47], which subsequently induces [Ca2+]i -elevation in neighbouring cells via paracrine purinergic signalling[48,49]. In fact, hemichannel-linked ATP-release plays a major role in cell-to-cell propagation of Ca2+-waves[37], which have been demonstrated to facilitate spread of inflammation along the vascular endothelium. Interestingly, PPADS protected mice against TNF-induced mortality and hypothermia, suggesting that purinergic receptor activation is contributing to TNF-induced pathology. BAPTA-AM on the other hand only protected mice against TNF-induced hypothermia and renal vascular permeability, but could not rescue against mortality, presumably because BAPTA-AM does not only inhibit pathological Ca2+-signalling, but also interferes with normal cell function. As a result, organ function may be disturbed by BAPTA-AM thereby compromising the function of heart, liver, kidney, brain and others, which may tip the mortality balance and obscure the protective potential.The causal relation between vascular permeability and mortality is still a matter of debate[8]. However, different strategies for ameliorating microvascular leakage in several mouse models of sepsis were associated with better survival outcome[8]. Interestingly, these protective effects were not associated with lower inflammatory cytokine levels, as found here and in another study, investigating the role of receptor interacting protein kinase (RIPK) 1-dependent necroptosis in TNF-induced SIRS[3]. Although the mechanisms by which vascular permeability is induced are still not fully understood, it is conceivable that excessive opening of hemichannels upon TNF-induced changes in [Ca2+]i could lead to detrimental outcomes in cells, via a cellular imbalance of ionic/molecular gradients[17,18] and a subsequent osmotic water flow[50]. Indeed, the contribution of open hemichannels to cell death induction has been debated in various studies[28,41,46] and has been reported in retinal ECs under ischemic conditions[41]. However, in our study, the TNF challenge did not promote renal cell death, as quantified by TUNEL staining, suggesting it was not causative for the observed TNF-induced renal permeability. In contrast, in the liver, TNF-induced endothelial permeability was shown to be induced by RIPK1-dependent necroptosis[3]. Another pathway underlying permeability can be attributed to Ca2+ and CaMKII function[38]. CaMKII has been linked to myosine light chain (MLC)- and MLC kinase-phosphorylation[51], which are importantly involved in vascular endothelial barrier dysfunction[38,39,52,53]. Our finding of decreased renal vascular leakage with KN-93CaMKII inhibition points to involvement of a Ca2+/CaMKII-dependent cascade, which is a central hub in the signalling cascade leading to endothelial barrier leakage[38].These findings emphasize the specific contribution of Cx43 hemichannels in inducing vascular permeability and blocking these channels protects against TNF-induced vascular leakage, hypothermia and eventually mortality. Limitations of the present study are that the peptides used have a short life-time and low in vivo efficacy and that the TNF-induced SIRS mice model has limited relevance for the complex condition of human SIRS/sepsis. As a result, further studies are needed to unravel the potential role of Cx43 targeted therapies in the clinical setting of SIRS treatment.
Materials and Methods
Cells
HeLa cells, stably transfected with Cx43[19,29,54], were cultured in Dulbecco’s modified eagle medium (Invitrogen, Ghent, Belgium), supplemented with 10% fetal bovine serum, 1% sodium pyruvate, 2 mM glutamine, 10 µg/ml streptomycin, 10 U/ml penicillin, 0.25 µg/ml fungizone (Invitrogen, Ghent, Belgium) and 1 µg/ml puromycin (Sigma-Aldrich, Bornem, Belgium). HeLa-WT cells were grown in the medium without puromycin. MouseGJA1 gene was cloned into the EcoRI/BamHI restricted cloning site of the expression vector pMJgreen. Cytomegalovirus promoter was used. The vector also contains a puromycin N-acetyl-transferase (Pac) gene encoding region. EA.hy926human ECs, a hybrid clone generated by fusing HUVECs with A549 cells, were cultured in DMEM, supplemented with 10% FBS, 1% L-glutamine, 0.4% sodium pyruvate and 2% HT-supplement (Invitrogen, Ghent, Belgium). All cells were cultured at 37 °C in a 10% CO2 atmosphere and were tested for mycoplasma on a regular basis.
Reagents and antibodies
Recombinant mouseTNF and humanTNF were produced in Escherichia coli and purified (>95%) in the VIB Protein Core (IRC, Ghent, Belgium). The biological activity of murineTNF (in vivo) and humanTNF (in vitro) was 7.94 × 109 IU/mg and 6.8 × 107 IU/mg respectively, and was determined using an MTT [3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide] assay. Peptides (purity > 95%) were purchased from Pepnome (China) and Genosphere Biotechnologies (Paris, France). Endotoxin contamination was checked by a Limulus Amebocyte Lysate assay and was <1.0 EU/mg. Gap27 (SRPTEKTIFII), TAT-Gap19 (YGRKKRRQRRR-KQIEIKKFK), Gap19 (KQIEIKKFK), TAT-CT9 (YGRKKRRQRRR-RPRPDDLEI), CT9 (RPRPDDLEI) and TAT (YGRKKRRQRRR) were diluted in endotoxin-free phosphate-buffered saline (PBS) or pipette solution for in vivo or in vitro use respectively. BAPTA was purchased from Invitrogen (B1212). BAPTA-AM (Invitrogen, B6769) was dissolved in dimethylsulfoxide (DMSO) (+0.01% pluronic® (Invitrogen)) and further diluted in endotoxin-free PBS for in vivo use. Pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid (PPADS, Sigma-Aldrich), and KN-93 (Calbiochem) were dissolved in DMSO and further diluted in endotoxin-free PBS for in vivo use. Fluorescein isothiocyanate (FITC)-dextran (4kDa; Sigma-Aldrich) was used in vascular permeability studies.
Electrophysiological recording
Subconfluent cultures of HeLa-Cx43 cells and EA.hy926 cells were seeded on 13-mm-diameter glass coverslips (Knittel Glaser, Novolab, Geraardsbergen, Belgium) and experiments were performed at subconfluency the next day. All recordings were performed in the presence of extracellular Ca2+ and Mg2+ and under conditions of K+-channel blockade with Cs+, Ba2+ and TEA+. Cells were bathed in a recording chamber filled with a modified Krebs-Ringer solution, consisting of (in mM): 150 NaCl, 6 CsCl, 2 MgCl2, 2 CaCl2, 5 glucose (10 for EA.hy926 cells), 5 HEPES, 1 BaCl2 and 2 Pyruvate, with pH adjusted to 7.4. The standard whole-cell recording pipette solution was composed of (in mM): 130 CsCl, 10 NaAsp, 0.26 CaCl2, 5 HEPES, 2 EGTA, 5 TEA-Cl and 1 MgCl2, with pH adjusted to 7.2. For experiments on EA.hy926 cells, 5 mM MgATP was additionally added to the pipette solution. A baseline free intracellular Ca2+ ([Ca2+]i, applied through the whole cell recording pipette) of 50 nM, as well as other concentrations (250, 500 and 1000 nM), were calculated with Webmax Standard software (http://www.stanford.edu/~cpatton/webmaxcS.htm). In experiments where cells were challenged with TNF, the pipette EGTA concentration was 2 mM for HeLa-Cx43 cells and 0.1 mM for EA.hy926 cells; for Ca2+ chelation experiments aimed at suppressing [Ca2+]i changes, EGTA was changed to 10 mM BAPTA. Gap19 and CT9 peptides (100 µM) were added to the pipette solution. Cells were exposed to recombinant humanTNF via a fast local perfusion system. An EPC 7 PLUS patch-clamp amplifier (HEKA Elektronik, Lambrecht, Pfalz, Germany) was used for single channel recordings. Data were acquired at 6 kHz using a NI USB-6221 data acquisition device from National Instruments (Austin, TX, USA) and WinWCP acquisition software (designed by Dr. J. Dempster; University of Strathclyde, UK). All currents in whole-cell configuration were filtered at 1 kHz (7-pole Besselfilter). For single channel analysis, holding currents were subtracted from the recorded current traces, giving traces that only contained unitary current events. Unitary conductances were calculated from the elementary current transitions Δi as: γ = Δi/Vm. From these data, we constructed all-point conductance histograms that displayed one or more Gaussian distributions. These were fit by a probability density function assuming independent channel opening[19,29,55,56]. Channel activity was quantified from the charge transfer Qm associated with unitary currents; this was done by integrating the unitary current traces over the duration of the voltage step as: Qm = ∫idt. Unitary events in the tail currents were counted manually.
Ca2+ imaging
HeLa-Cx43 cells were seeded onto 18-mm-diameter glass coverslips (Knittel Glaser, Novolab, Geraardsbergen, Belgium), and experiments were performed at subconfluency the next day. The cells were loaded with 5 µM fluo3-AM in HBSS-HEPES (1 mM CaCl2, 0.81 mM MgSO4, 13 mM NaCl, 0.18 mM Na2HPO4, 5.36 mM KCl, 0.44 mM KH2PO4, 5.55 mM d-glucose, and 25 mM HEPES) for 45 min at 37 °C. After 45 min, coverslips were washed and then left for an additional 15 min at 37 °C in HBSS-HEPES to allow for de-esterification. Cells were thereafter transferred to an inverted epifluorescence microscope (Eclipse TE 300, Nikon Belux, Brussels, Belgium) equipped with a superfusion system allowing fast solution changes. Superfusion was switched off during the registration of oscillatory activity. Images were taken every second with a 40x oil-immersion objective and an electron-multiplying CCD camera (Quantem 512SC, Photometrics, Tucson, AZ). We used a Lambda DG-4 filterswitch (Sutter Instrument Company, Novato, CA) to deliver excitation at 482 nm and captured emitted light via a 505-nm long-pass dichroic mirror and a 535-nm bandpass filter (35-nm bandwidth). Recordings and analysis were done with custom-developed QuantEMframes and Fluoframes software written in Microsoft Visual C++ 6.0. Oscillatory activity was recorded in a 10 min observation window.
Mice
All mice were bred in specific pathogen-free or in conventional animal facilities, and were males between 8–12 weeks during all the experiments. As connexin expression levels can be altered by the hormonal cycle, male mice were used to limit variability related to the hormonal status. Mice were housed in air-conditioned, temperature-controlled rooms with 14/10-hour light/dark cycles. Food and water were provided ad libitum. C57BL/6J WT mice were purchased from Janvier (Le Genest, France). All mice experiments were organized in accordance with institutional, national, and European animal regulations, and got approved by the animal ethics committee at Ghent University (ECD 2013–064).
TNF induced Lethal Shock – Monitoring and Sampling
Peptides were diluted in endotoxin-free PBS (Sigma-Aldrich) and injected i.v. in a volume of 200 µl at 5 or 10 mg/kg for TAT-Gap19, 5 or 10 mg/kg for TAT, 10 or 15 mg/kg for TAT-CT9, and 25 mg/kg for Gap27, 15 min before i.v. injection of murineTNF (7.5–15 µg/20 g) in 200 µl endotoxin-free PBS (pH 6.8) (prophylactic administration). Therapeutic administration consisted of i.v. injection of 5 mg/kg of TAT-Gap19 30 min after TNF. BAPTA-AM (2 mM in DPBS (6% DMSO)) and KN-93 (10 mg/kg in DPBS (6% DMSO)) were injected i.v. respectively 30 min and 60 min before TNF injection. Control injections consisted of an equal amount (i.v.) of DPBS (6% DMSO). PPADS (50 mg/kg) was injected intraperitoneally (i.p.) 15 min before injection of TNF. Survival and body temperatures were monitored until 5 days post TNF-injection. Rectal body temperatures were recorded with an electric thermometer (Model 1; Comark Electronics, Norwich, UK), and dead mice (25 °C) are included in all body temperature graphs, as was previously implemented[1,57]. Blood and tissue samples were collected at different time points after injection as outlined in the results section. Blood was collected by cardiac or retro-orbital puncture. Vascular permeability was evaluated as previously described[58].
Immunostaining
Tissue was fixed with 4% paraformaldehyde, embedded in paraffin, sectioned at 5 µm and dewaxed before staining procedure was initiated. Cell death was identified by terminal deoxynucleotidyl-transferase dUTP nick-end labeling (TUNEL) staining (TMR in situ cell death detection kit; Roche) in accordance with the manufacturer’s instructions, 6 hr after TNF injection. Sections were counterstained with Hoechst (Sigma-Aldrich). Micrographs were acquired using a Zeiss Axioscan Z.1 slide scanner (Carl Zeiss, Jenna, Germany) at 20x magnification, with a Hamamatsu ORCA Flash4 camera (Hamamatsu Photonics), and illuminated with an HXP 120V light source. Analysis was performed using VolocityⓇ (PerkinElmer, UK) and QuPath (GitHub) softwares.
Determination of LDH, Cytokines and P-selectin
Levels of LDH were measured by an automated clinical analyzer in the University Hospital of Ghent. Cytokine levels of IL-6 and chemokine (C-X-C motif) ligand 1 (CXCL-1) were determined with Luminex magnetic bead-based assays (R&D Systems, Biotechne). Plasma P-selectin levels were measured through a Quantikine ELISA kit (R&D Systems, Biotechne).
Statistics
Statistical analysis was performed in GraphPad Prism (v.7.0). All Kaplan-Meier survival curves were analysed by the log-rank Mantel-Cox test. Body temperatures and vascular permeability assays were analysed by a two-way ANOVA with Tukey’s multiple comparisons test to compare more than two groups, and by a two-way ANOVA with Sidak’s multiple comparisons test to compare two groups. A Shapiro-Wilk normality test indicated normally distributed data. All immunohistochemical and serum parameters were compared with a one-way ANOVA with a Bonferroni post-test to compare all pairs. In the electrophysiology recordings, comparisons between two groups were done with a two-tailed t-test and comparison of more than two groups was performed with a one-way ANOVA and Bonferroni post-hoc test. Significant results are indicated with *for p < 0.05; **for p < 0.01; ***for p < 0.001 or ****for p < 0.0001.Supplementary Figures and Legends
Authors: Juan C Sáez; Kurt A Schalper; Mauricio A Retamal; Juan A Orellana; Kenji F Shoji; Michael V L Bennett Journal: Exp Cell Res Date: 2010-06-02 Impact factor: 3.905
Authors: Roosmarijn E Vandenbroucke; Eline Dejonckheere; Philippe Van Lint; Delphine Demeestere; Elien Van Wonterghem; Ineke Vanlaere; Leen Puimège; Filip Van Hauwermeiren; Riet De Rycke; Conor Mc Guire; Cristina Campestre; Carlos López-Otin; Patrick Matthys; Georges Leclercq; Claude Libert Journal: J Neurosci Date: 2012-07-18 Impact factor: 6.167
Authors: Mélissa Bol; Nan Wang; Marijke De Bock; Benjamin Wacquier; Elke Decrock; Ashish Gadicherla; Kelly Decaluwé; Bert Vanheel; Harold Victor Maria van Rijen; Dmitri Vadim Krysko; Geert Bultynck; Geneviève Dupont; Johan Van de Voorde; Luc Leybaert Journal: Cardiovasc Res Date: 2016-09-27 Impact factor: 10.787
Authors: Helen V Danesh-Meyer; Nathan M Kerr; Jie Zhang; Elizabeth K Eady; Simon J O'Carroll; Louise F B Nicholson; Cameron S Johnson; Colin R Green Journal: Brain Date: 2012-02 Impact factor: 13.501
Authors: K J Tracey; B Beutler; S F Lowry; J Merryweather; S Wolpe; I W Milsark; R J Hariri; T J Fahey; A Zentella; J D Albert Journal: Science Date: 1986-10-24 Impact factor: 47.728
Authors: Rudolf Lucas; Yalda Hadizamani; Perenlei Enkhbaatar; Gabor Csanyi; Robert W Caldwell; Harald Hundsberger; Supriya Sridhar; Alice Ann Lever; Martina Hudel; Dipankar Ash; Masuko Ushio-Fukai; Tohru Fukai; Trinad Chakraborty; Alexander Verin; Douglas C Eaton; Maritza Romero; Jürg Hamacher Journal: Front Physiol Date: 2022-02-21 Impact factor: 4.755
Authors: Raf Van Campenhout; Ana Rita Gomes; Timo W M De Groof; Serge Muyldermans; Nick Devoogdt; Mathieu Vinken Journal: Int J Mol Sci Date: 2021-03-28 Impact factor: 6.208
Authors: Chelsy L Cliff; Bethany M Williams; Christos E Chadjichristos; Ulrik Mouritzen; Paul E Squires; Claire E Hills Journal: Int J Mol Sci Date: 2022-01-06 Impact factor: 5.923